Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms GR 1803, GR-1803, GR1803 |
Target |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 1 | CN | 09 May 2022 |
CTR20220402 (EHA2024) Manual | Phase 1 | 50 | (All pts) | wbfamcewyn(zspiuwxckd) = bqccxuboll pbplzabvjl (kwfwghceyo ) View more | Positive | 14 May 2024 | |
(180ug/kg) | ggbjwyhtms(aswdotvwvg) = gqnydaggeq fwznxvvfav (wkpqvrqzuq ) | ||||||
Phase 1 | Relapse multiple myeloma BCMA | CD3 | 50 | mqnlcihgar(fhcogypiqr) = 70% (32% Gr ≥ 3) uhwfkyuegx (oezrzfeqgn ) View more | Positive | 14 May 2024 |